Compare Rivian Automotive, Inc. (RIVN) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rivian Automotive, Inc. vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Rivian Automotive, Inc. trades at $14.2 (market cap $20.75B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 2.8× Rivian Automotive, Inc.'s market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Rivian Automotive, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Rivian Automotive, Inc. for 61 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| RIVN | TAK | |
|---|---|---|
Market Cap | $20.75B | $58.74B |
Volume | 26,144,654 | 3,110,994 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.45 | $19.05 |
52-Week Low | $12.50 | $13.23 |
Typical Hold Time | 61 Days | 0 Days |
Enterprise Value | $20.79B | $86.65B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rivian Automotive (RIVN) trades at $14.34, down 1.17% amid bearish technical signals despite strong Q3 2026 delivery growth of 46% to 19,248 vehicles. The company maintains negative profitability with a -54.95% net income margin but shows improving cash flow trends with operating losses narrowing from -$5.1B in 2022 to -$779M in 2025. Recent news highlights R2 SUV production ramp and autonomy technology development, though the stock faces pressure from unchanged 2026 guidance and a recent R2 battery pack recall.
Rivian presents a high-risk growth opportunity with significant cash burn but improving operational efficiency. The path to profitability depends on successful R2 scaling and future autonomy revenue, while near-term risks include execution challenges and competitive EV market pressures. Analyst consensus remains cautiously optimistic with a $16.89 price target representing 18% upside potential.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
